



Lonza Acquisition of Vivante GMP Solutions Frequently Asked Questions

When did Lonza acquire Vivante?

The acquisition was completed on August 27, 2010.

Who is Vivante GMP Solutions?

Vivante is a niche CMO with strong expertise in the viral vaccine and viral vector markets. Vivante provides its clients with flexible, disposable, scalable viral-based GMP production knowledge and capabilities to convert early-stage production into robust and scalable therapeutic products for clinical and commercial use. Vivante offers its clients access to its intellectual property portfolio, which includes quality and validation systems, and broad GMP knowledge. Vivante operates a state-of-the-art GMP clean room facility which includes production and fill/finish capabilities, along with high quality Research and Development and Quality Control operations. In addition to its GMP manufacturing services, Vivante offers process development and optimization, Quality Control analytical testing, and both on- and off-site GMP product storage and distribution to clinical trial sites. One of the Vivante team's many technical accomplishments was its production of the adenoviral reference material (ARM), which serves today as the industry standard against which all other U.S. adenoviral products are measured.

Who is Lonza?

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers' needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts, which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research products, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.

Why did Lonza acquire Vivante?

In order to continue Lonza's commitment to high-quality scalable custom manufacturing for Biotherapeutics, Lonza has decided to expand its offering to the viral vaccine and viral vector markets. Vivante's current capabilities, technical expertise, and business pipeline will accelerate Lonza's entry into this innovative field. Much of Lonza's current client base has expansive portfolios centered on a variety of therapeutics. Most recently, Lonza launched a new specialized medium for virus production in PerC6 Cells, thus continuing our commitment to grow with our customer's market initiatives. Incorporating Lonza's leading protein and cell therapy capabilities, full line of custom media and disposables, global process development and manufacturing experience along with Vivante's strong viral-based offering, will provide the biotech and pharmaceutical industry with a trusted partner for their comprehensive pipeline.

Why did Vivante choose to be acquired by Lonza?

Vivante's successful viral platform has laid the foundation for expansion into new and innovative viral systems along with dependable commercial manufacturing possibilities. Vivante recognized Lonza as the perfect partner to facilitate and enhance these growth opportunities. Lonza's global reach, protein and cell therapy technical expertise, and financial strength proved to be a great asset to Vivante's viral business. Like other biologics, customers with viral-based products advancing through the regulatory process are looking for a stable, reliable supplier with solid GMP competencies. Lonza has a proven track record of providing this dependable platform for both emerging and established biopharmaceutical companies.

What does the acquisition mean for Vivante customers?

Vivante customers should not expect to see any significant changes to daily interactions related to their current projects. Customers should continue to contact their Vivante client service team member with any questions

August 2010

regarding existing or upcoming projects. Vivante-GMP Solutions will now be called Lonza Houston, Inc. In addition, all Lonza Walkersville customer service teams will be able to direct any viral-based inquiries to the correct contact point.

What are Vivante's development and manufacturing capabilities?

Vivante provides full-service process development, GMP manufacturing, analytical assay development and validation, fill and finish, stability testing, regulatory support, and product storage and distribution for viral-based technologies such as vaccines and gene therapy deliver vectors.

What are Lonza's products and services?

Lonza Bioscience provides products ranging from cell culture and molecular biology tools for life science research to custom media and disposables for the production of biotherapeutics. Lonza also offers an extensive portfolio of products for endotoxin detection, informatics, and microbial biology used by some of the world's leading quality control laboratories. Lonza specializes in primary/stem cell systems, including process development and manufacturing of cellular therapeutics. In addition, as a leading contract manufacturing organization, Lonza offers custom services for the production of fine chemicals, HAPIs, antibodies, ADCs and other molecules. These services range from early expression technologies for mammalian and microbial systems to large scale commercial manufacturing capacity.

Where can I discuss my projects with Vivante GMP from here forward?

Current Vivante clients should continue to work through their service contacts at the Houston site.

Vivante GMP, Inc, now Lonza Viral-based Therapeutics may be contacted the following ways:

Viralservices@lonza.com
www.lonza.com/viral
info@Vivante-GMP.com
Phone: 713.568.6190 X 4012
8066 El Rio Street
Houston, TX 77054
U.S.A.

You will be contacted shortly regarding details such as changes on payments of invoices. For the most up-to-date information on Lonza's viral-based therapeutics offering, please visit www.lonza.com/viral or www.vivante-gmp.com.

Where can I find out more about Lonza's products and services?

Catalog products may be ordered via phone, fax or online:

USA	Phone 800-638-8174 or 301-898-7025
	Fax 301-845-8338
	Online www.lonza.com (see Online Catalog)
Europe	Phone +32 (0) 87 321 611
	Fax +32 (0) 87 351 967
	Online www.lonza.com (see Online Catalog)

Customers outside of the USA and Europe should contact their local distributor to place orders. For the most up-to-date information on distributors of Lonza products visit www.lonza.com.

Is my Vivante quotation still valid?

Yes. If your quotation is close to its expiration date, please contact your Vivante representative.